The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non–Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of our study was to investigate the value of baseline and preoperative neutrophil-to-lymphocyte ratio (NLR) in predicting the pathological response and disease-free survival (DFS) of neoadjuvant chemotherapy alone or combined with programmed cell death-1 (PD-1) checkpoint inhibitors in patients with resectable non‒small cell lung cancer (NSCLC). Materials and methods: Resectable NSCLC patients who underwent neoadjuvant chemotherapy alone or combined with PD-1 checkpoint inhibitors between January 2018 and January 2020 were included. Peripheral venous blood samples of the patients were collected within 3 days prior to the first neoadjuvant treatment and within 3 days prior to surgery. Results: A total of 79 patients in neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group and 89 patients in neoadjuvant chemotherapy alone group were included. Thirty-five point four percent of the patients achieved pathological complete response (pCR) in neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group, whereas only 9.0% reached pCR in the group of neoadjuvant chemotherapy. High NLR level were correlated with poor pathological response and DFS in neoadjuvant chemotherapy or combined with PD-1 checkpoint inhibitors group. Multivariate analysis revealed that baseline NLR could independently predict pathological response and DFS in the neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group. Conclusion: High NLR level were correlated with poor pathological response and shorter DFS in patients with NSCLC undergoing neoadjuvant chemotherapy or combined with PD-1 checkpoint inhibitors. Meanwhile, baseline NLR could independently predict response to pathological response and DFS, revealing its potential as a screening tool in NSCLC patients who received neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors.
Abstract
Purpose: The aim of our study was to investigate the value of baseline and preoperative neutrophil-to-lymphocyte ratio (NLR) in predicting the pathological response and disease-free survival (DFS) of neoadjuvant chemotherapy alone or combined with programmed cell death-1 (PD-1) checkpoint inhibitors in patients with resectable non‒small cell lung cancer (NSCLC). Materials and methods: Resectable NSCLC patients who underwent neoadjuvant chemotherapy alone or combined with PD-1 checkpoint inhibitors between January 2018 and January 2020 were included. Peripheral venous blood samples of the patients were collected within 3 days prior to the first neoadjuvant treatment and within 3 days prior to surgery. Results: A total of 79 patients in neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group and 89 patients in neoadjuvant chemotherapy alone group were included. Thirty-five point four percent of the patients achieved pathological complete response (pCR) in neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group, whereas only 9.0% reached pCR in the group of neoadjuvant chemotherapy. High NLR level were correlated with poor pathological response and DFS in neoadjuvant chemotherapy or combined with PD-1 checkpoint inhibitors group. Multivariate analysis revealed that baseline NLR could independently predict pathological response and DFS in the neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors group. Conclusion: High NLR level were correlated with poor pathological response and shorter DFS in patients with NSCLC undergoing neoadjuvant chemotherapy or combined with PD-1 checkpoint inhibitors. Meanwhile, baseline NLR could independently predict response to pathological response and DFS, revealing its potential as a screening tool in NSCLC patients who received neoadjuvant chemotherapy combined with PD-1 checkpoint inhibitors.
참고문헌 (28)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Liu L, "Research progress of KRAS mutation in non-small cell lung cancer", Zhongguo Fei Ai Za Zhi, 21, pp.419~424 (2018)
- Antonia SJ, "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
- Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell Lung Cancer", N Engl J Med, 378, pp.2078~2092 (2018)
- Paz-Ares L, "Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer", N Engl J Med, 379, pp.2040~2051 (2018)
- Ling Y, "Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes", NPJ Precis Oncol, 4, pp.32~ (2020)
- Liu J, "Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease", Cancer Discov, 6, pp.1382~1399 (2016)
- Yi JS, "Immune activation in early-stage non-small cell lung cancer patients receiving neoadjuvant chemotherapy plus ipilimumab", Clin Cancer Res, 23, pp.7474~7482 (2017)
- Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
- Russo A, "Neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), and outcomes with nivolu-mab in pretreated non-small cell lung cancer(NSCLC) : a large retrospective multicenter study", Adv Ther, 37, pp.1145~1155 (2020)
- Wang Y, "Prognostic value of the pretreatment systemic immune-inflammation index(SII)in patients with non-small cell lung cancer : a meta-analysis", Ann Transl Med, 7, pp.433~ (2019)
- Pisters KM, "Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy : imp-lications for the design of future non-small-cell lung cancer combined modality trials", J Clin Oncol, 11, pp.1757~1762 (1993)
- Betticher DC, "Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer : a multicenter phase II trial", J Clin Oncol, 21, pp.1752~1759 (2003)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140, pp.883~899 (2010)
- Li Q, "Treatment-related lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy", Ann Surg Oncol, 26, pp.2882~2889 (2019)
- 허재성, "Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer", Cancer Research and Treatment, 48(1), pp.232~239 (2016), 대한암학회[DOI]
- Fang P, "High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer", Radiother Oncol, 128, pp.584~590 (2018)
- Cullinane C, "Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis", Clin Breast Cancer, 20, pp.e675~e681 (2020)
- Choi JE, "Perioperative neutrophil : lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery : a retrospective study", Cancer Med, 4, pp.825~833 (2015)
- Dal Bello MG, "The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer(NSCLC)patients", J Transl Med, 17, pp.74~ (2019)
- Kojima H, "Prognostic impact of the number of involved lymph node stations in patients with completely resected non-small cell lung cancer : a proposal for future revisions of the N classification", Gen Thorac Cardiovasc Surg, 68, pp.1298~1304 (2020)
- Yingjia Wu, "Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers", Cancer Research and Treatment, 53(1), pp.172~183 (2021), 대한암학회[DOI]
- Powell A, "Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma", BJS Open, 4, pp.416~423 (2020)
- Ferrucci PF, "Baseline neutrophils and deri-ved neutrophil-to-lymphocyte ratio : prognostic relevance in metastatic melanoma patients receiving ipilimumab", Ann Oncol, 27, pp.732~738 (2016)
- Bagley SJ, "Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer", Lung Cancer, 106, pp.1~7 (2017)
- Zhang H, "Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer", Am J Surg, 210, pp.526~535 (2015)
- Li A, "Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer", Future Oncol, 15, pp.3233~3242 (2019)